JNJ240712P152500
- 2.70
- 0.000.00%
Johnson & Johnson Newsroom
What to Expect in the Week Ahead (GS, JNJ, TSM, and NFLX Earnings; Retail Sales and Housing Starts)
Earnings in the week ahead could be the next catalyst for a broadening market
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Financial Stocks Deliver Profits in Q2 Amid Rebound in Investments - Earnings Scorecard
Lots of Earnings, Price of Stamps Increasing: What to Watch
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
Stifel Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $155
Stifel analyst Rick Wise maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $155.According to TipRanks data, the analyst has a success rate of 57.5% and a
Earnings Preview: JNJ to Report Financial Results Pre-market on July 17
$Johnson & Johnson(JNJ.US)$ is scheduled to release its financial results pre-market on July 17. Earnings PreviewAnalysts estimate $Johnson & Johnson(JNJ.US)$ to post revenue of USD22.31 billion for 2
Stifel Nicolaus Remains a Hold on Johnson & Johnson (JNJ)
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $167.According to TipRanks data, the analyst has a success rate of 64.8
Johnson & Johnson (JNJ.US) announced the acquisition of Yellow Jersey will bring a cost impact of 1.25 billion US dollars, it is expected to dilute this year's adjusted EPS by 0.56 US dollars.
Johnson & Johnson announced on Thursday that the acquisition of Yellow Jersey Therapeutics will result in an expense impact of approximately $1.25 billion.
J&J to Recognize $1.25B Impact From Yellow Jersey Acquisition
Express News | Johnson & Johnson Completes The Acquisition Of Yellow Jersey, A Demerged Subsidiary Of Numab Therapeutics To Secure The Global Rights To Nm26, In An All-cash Transaction Of Approximately $1.25 Billion, As Announced On May 28, 2024
Express News | Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of Nm26
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $163
Wells Fargo analyst Larry Biegelsen maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $163.According to TipRanks data, the analyst has a success rate of 58.1%
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' to Meet 2024 Guidance, Goldman Says
U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17.As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and
Citi Research's AI Hedge Stocks - Part II
Johnson & Johnson (JNJ): One of the Best Blue Chip Dividend Stocks Right Now According to Hedge Funds?
Johnson & Johnson (NYSE:JNJ) is an American pharmaceutical industry company that also specializes in healthcare consumer products.
Express News | On Monday, Johnson & Johnson Agreed To Pay $50M To Settle Claims Related To A Terminated Manufacturing Deal With Emergent BioSolutions Related To Johnson & Johnson's Covid-19 Vaccine - 8K
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing
Emergent Biosolutions (EBS) said in a regulatory filing Monday that its subsidiary, Emergent Manufacturing Operations Baltimore, and Johnson & Johnson's Janssen Pharmaceuticals unit have agreed to settle all disputes related to a manufacturing services agreement for Johnson & Johnson's COVID-19 vaccine.
Is the second bull market really here? The Nikkei rose 2% and hit a new high again.
Is the Japanese stock market starting a new bull market?